Novartis, PTC Therapeutics and Huntington's

Novartis in up to $2.9 billion licensing deal for PTC Therapeutics Huntington's disease drug
Swiss drugmaker Novartis will pay up to $2.9 billion for PTC Therapeutics' promising experimental drug for a neurological disorder called Huntington's disease, sending the U.S.-based biotech's shares up about 14% on Monday.
Novartis and PTC Therapeutics link to develop Huntington’s therapy
Novartis has entered a worldwide licensing and partnership agreement with PTC Therapeutics to develop PTC518, a potential oral therapy for Huntington's disease (HD). The PTC518 Huntington's disease programme also encompasses related molecules.
PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program
On Monday, PTC Therapeutics, Inc. (NASDAQ:PTCT) signed an exclusive global license and collaboration agreement with Novartis AG (NYSE:NVS) for its PTC518 Huntington’s disease program, which includes related molecules.
Novartis wagers billions of dollars on PTC Huntington’s drug
At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly 250-person study that should produce results next year.
PTC Therapeutics boosted by Novartis rights deal for Huntington’s program
The potential $2.9 billion deal stands the New Jersey company in good stead after recent disappointing results in its ALS program.
Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion
Novartis will make an upfront payment of $1.0 billion to PTCT and the latter will also be eligible for up to $1.9 billion in development, regulatory and sales milestones. NVS will also share profits in the United States (40% PTC and 60% Novartis) and pay tiered royalties on ex-US sales.
PTC Therapeutics Stock Soars on Novartis Licensing Agreement
Shares of PTC Therapeutics surged Monday when the pharmaceutical firm announced it struck a nearly $2 billion license and collaboration deal with Novartis.
Novartis, PTC Ink Up-to-$2.9B Huntington’s Disease Collaboration
Novartis will partner with PTC Therapeutics to develop PTC’s PTC518 Huntington's disease program and an unspecified number of related molecules, through an up-to-$2.9 billion exclusive global license and collaboration agreement.
Novartis signs licensing deal worth up to $2.9B with PTC Therapeutics
The Swiss pharmaceutical company invests in a PTC Therapeutics program to develop treatment for Huntington’s disease.
Novartis Pays Up to $2.9B in Huntington’s Deal With PTC
Monday’s agreement comes days after PTC discontinued the development of another asset, utreloxastat, due to disappointing Phase II data in amyotrophic lateral sclerosis.
PTC Inks License And Collaboration Deal With Novartis For PTC518 Huntington's Disease Program
Biopharmaceutical company PTC Therapeutics, Inc. (PTCT) announced Monday the signing of an exclusive global license and collaboration
FierceBiotech2d
Novartis pays PTC $1B upfront for midphase Huntington's program, reestablishing itself in R&D race
Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...
Stocktwits on MSN1d
PTC Therapeutics Stock Eyes Further Rally After Price-Target Hikes On Huntington’s Therapy Deal With Novartis: Retail Buzz Grows
Shares of PTC Therapeutics Inc. climbed nearly 1% pre-market Tuesday, poised to extend their rally to levels last seen in ...
Yahoo Finance14h
PTC Therapeutics price target raised to $71 from $47 at UBS
PTC Therapeutics on Monday announced a global licensing and collaboration agreement with Novartis (NVS) for its Huntington’s Disease program, PTC518, under which PTC will receive $1B at ...